click enter text
februari issu monthli controversi report
report cover bull/bear case current controversi rel growth
prospect us eu global pharmaceut compani
overal sector view mix fundament decent total sharehold return
averag group valuat modestli histor level market-weight
under-perform ep growth decent intermedi term long-
astrazeneca outperform long-term ep growth almost peer
group averag must stock sourc upsid option
bristol-my squibb outperform celg deal add controversi
controversi pro-forma ep cheap ignor
peer-perform solid prospect explain high expect
hope pull-back
glaxosmithklin peer-perform plaudit chang thing eventu
consum spin-out show impli price-to-earnings pharma low slowli
becom interest
merck outperform ye expect keytruda high
one driver growth gardasil valuat still fair ep outlook
novarti outperform feel good catalyst-driven stori check
multipl box wish ep growth higher valuat reason
peer-perform major split-up come
outlook base pipelin outlook okay great ep
next essenti flat valuat limit downsid
roch peer-perform on-going tug-of-war prospect
biosimilar exposur market will look past latter risk
cap price-to-earnings multipl upsid growth model lowest group
sanofi peer-perform slowli return better growth catalyst-lit
arguabl downsid support low valuat
report limit sole use client wolf research pleas refer disclosur section locat end
www wolferesearch com/disclosur write us wolf research llc lexington avenu suit new york ny
analyst certif disclosur
page
tabl content
page
overal perspect global pharma sector exhibit temper view
toward drug industri overal industri fundament mix neither worst best time
think tailwind versu headwind latter moment posit side
gener product trend phase success rate among biopharmaceut compani
turn last sever year yet sever cover compani still individu late -stage
pipelin thin rel much spend annual rel larg size
seem overcapac mani compani chase smaller residu
opportun neg side drug price remain squar spotlight esp us variou
propos aim lower drug spend implement intermediate-term chang like
increment potenti materi chang long-term rule
still also variou patent loss big drug across industri lay ahead never end realli
ebb flow vari compani drug compani valuat reflect mani challeng
alreadi group trade modest discount rel price-to-earnings multipl basi total
sharehold return basi outlook reason averag ep growth average ep compound-annual-growth-rate
averag dividend yield lead us sector rate market weight
exhibit overal perspect global pharma sector updat
page
major theme exhibit show think major theme sourc
news flow come year
exhibit major theme anticip
drug price outlook varieti propos continu promulg histori suggest mani
like die vine scale back less oner propos
effect lobbi effort deep-pocket drug industri coupl congression inertia
impact reform measur gener requir act congress new law much shorter list
chang accomplish administr rule-mak process hh agenc
commerci side payer dynam quit differ public program side price
govern principl natur competit oppos govern regul
misconcept think privat payer simpli follow footstep govern despit
privat commerci payer nonetheless effect foster signific price competit sever
instanc one risk contempl next presidenti cycl democrat take white hous
congress substant polici chang could enact go
presidenti elect talk unsurprisingli surfac among democrat singl payer system would
bad healthcar subsector biopharmaceut
partial list potenti case actual chang date includ
page
away rebat heighten attent practic rebat
discount pharmaceut compani make payer return better market access drug
compani quick point insurers/pbm act unnecessari middleman
skim much revenu stream without pass along save insur
constitu current propos pass rebat consum point sale seem
momentum implement remain unanswer question term logist howev
stand today like much advers impact drug compani rather
payer issu implement like later
medicar part began allow medicar advantag plan limit manag part drug
close broadli bipartisan support shift away tradit buy bill
framework arguabl skew physician incent physician may ultim taken
mix allow payer better manag type drug recent propos benchmark price
basket intern price invari lower us price like becom realiti
view
medicar part recent propos address six protect class drug
insul aggress payer action new rule help pave way price competit see
report remov protect drug class statu come one chang
protect drug class could matter start manufactur requir offer
discount fund help close coverag gap info see close medicar donut
hole headwind ep small one
medicaid state medicaid program seek waiver grant author use
tradit formulari manag tool like formulari tri lower drug spend often lower
profit channel biopharmaceut compani medicaid spend drug roughli
state-level initi lack feder action individu state increasingli take
matter hand come initi tackl drug price exampl california
drug price transpar bill requir justif drug price increas certain level
push gener includ biosimilar free-market solut problem one
champion approach fda commission scott gottlieb free-market approach
idea foster price competit make sure gener approv bottleneck clear
part roadblock greater biosimilar usag evalu view reform-lit
someth industri would gener support lesser evil
exhibit use think impact us reform could global pharmaceut
compani put us drug spend relat global drug spend show split payer
channel us global drug spend us repres total us
simplist carv two main bucket commerci public program take-away
impact small chang us program get dilut given global revenu mix mnc
page
exhibit summar compani exposur us payer channel vari meaning
exhibit payer exposur us drug busi compani
page
companycommercialpart bpart info provid largest part drug keytruda largest part drug add info provid -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- novn vs peer average vs peer average vs peer vs total compani sale expos medicar vast major part add info provid -- -- -- -- -- -- -- -- -- approx compani irblack wr best guess base compani disclosur azn commerci includ non-contract sale gpo/ltc sale
valuat perform exhibit show forward price-to-earnings multipl coverag univers rel
last rel price perform coverag univers vs
last
exhibit valuat perform rel
compar growth rate exhibit show rel revenu ep growth rate cover
compani index three differ time period shown
view accur
page
exhibit compar revenu ep growth rate
exhibit base revenu analysi look growth profil cover compani collect
product market today exclud futur pipelin drug includ revenu divis
consum health anim health diagnost across two differ period intent
exhibit show longer stretch time compani biggest futur loss
contend usual due patent expir drug compani long-rang plan take
consider think much spend put behind potenti target
key point make
page
view view view reveneu growth ep growth ep growth reveneu growth ep growth revenu growth
view differ view least compani
smaller pure play compani tend fastest growth
smaller pure play compani also tend volatil base revenu
compani fortun enough posit base revenu growth least next
sever year patent expir cycl
basi half move neg growth territori order magnitud includ
exhibit base revenu growth
page
exhibit comp sheet cover stock certain larg cap therapeut name also shown
refer
factset wolf research price
page
azn w/o europ healthcar compani comparison cover pharma target multipl
rate price target summar exhibit
azn novn rate outperform like azn best novn
one notch lower lower long-term ep growth rel three
gsk san rate peer-perform gsk look intrigu
us
rate under-perform
exhibit wr summari rate price target
factset wolf research price
page
companyratingpric pt multipl epsu/d price u/d rel group astrazeneca azn squibb nv novn vx opchf rhhbi rog vx ppchf sni sasi pa pp average average return vs
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment bifurc viewpoint still support mani increasingli loath
pipelin prowess abil best phase pipelin optic look full
compound natur
binari event risk noth discret addit pipelin misstep rova-t failur would hurt
given imper lessen depend humira question anticip whether
pursu larger seem inevit manag say near-term
near-term outlook growth near-term decent question mark given recently-revis
steeper sale eros ex-u humira twice period stock like flat near-term
could boost share depend asset
long-term outlook good base model
valuat cheapest price-to-earnings bmi celg pro-forma price-to-earnings lower howev put floor support
net remain cautiou due uncertainti impact humira
biosimilar admittedli consensu concern singl product concentr risk
degre vastli exce compani cover product tail end life-cycle
odd name competit growth next year
substanti pressur earn begin think margin de-lever under-model
eu biosimilar humira launch sinc octob belief new money sit one
engag larger distinct possibl near-term manag true
word otherwis get hand meaning new product perhap stori get interest
disclos impair charg halt develop rova-t taho trial
updat resolv result disclos ibrutinib combin nab-paclitaxel
gemcitabin improv os compar placebo w/nab-paclitaxel gemcitabin arm
report earn revenu in-lin consensu miss ep
guidanc okay humira guidanc lower time within period due higher rate
eros ex-u also quietli suggest high-dos upadacitinib dead detail see
full postview ep miss guidanc okay except worsen humira eros
announc fda approv imbruvica plu gazyva line cll/sll base
studi show reduct risk progress death compar chlorambucil
page
announc fda accept upadacitinib nda prioriti review ra treatment base
select studi draft/propos label ra dose believ provid
maxim efficaci regulatori decis expect year
announc xeljanz post-market studi look bid significantli
pulmonari embol overal mortal compar bid tnfi arm activ
transit patient high dose low dose implic overal jak class safeti
percept relev upadacitinib
import upcom event next
read-out cll combo w/ rituximab allianc
competitor event earli azn acalabrutinib vs ibrutinib r/r cll elev cll
r/r trial acalabrutinib read later
read-out approv registr aml data present combo w/
bortezomib r/r mm bellini regulatori approv cll base
regulatori approv psoriasi start start ad hs
upadacitinib jak approv ra data
depatux-m egfr studi glioblastoma gbm concomit radiotherapi
tmz readout
humira biosimilar eros monitor multipl eu biosimilar enter octob
import monitor us biosimilar start enter januari six manufactur alreadi
agreement place samsung bioepi freseniu kabi sandoz momenta bi case still
outstand could theoret lead biosimilar entri
enbrel biosimilar patent litig septemb court rule expect earli outcom
favor sandoz erelzi could launch earlier expect would sudden/unexpect
page
competit pressur us humira well product compani off-
the-radar risk visibl slowli rise
 like activ given size humira hole eventu fill uncertainti time
doesnt near-term management claim big near-term recent result
humira parti yet even eu biosimilar launch global brand continu
grow margin high estim global oper margin also expir
cabilli patent lessen royalti pay serv partial off-set eu eros us
biosimilar dont launch long way away
phase pipelin full under-valued hand de-risk late-stag candid
street significantli manag expect jak leverag exist
humira relationship bundl jak forc favor payer access
b-cell tumor franchis imbruvica/venclexta great outlook imbruvica great
venclexta come onto scene interest product high margin high growth product
stock cheap lowest-in-the-group price-to-earnings multipl alreadi anticip humira biosimilar concern
stock under-valu taken context ep growth deliv near- mid-
term manag long-term guidanc right stock realli under-valu
alway buy solut stock would like react well unless equity-bas
transact could creat arb-rel pressur
humira fund compani biosimilar hurt expect stori killer
manag downward revis ex-u eros guidanc twice three month show may
difficulti predict futur humira trajectori could extend us well eu humira
profit higher investor expect view biosimilar uncertainti acut
could chang rebat environ us impact humira durabl abil
bundl pipelin drug humira abl thwart competit partli high level
rebat pay payer rebat paradigm chang discuss washington
take away one key advantag would also undermin bull-cas argument
bundl way payer cover new product like upadacitinib risankizumab
phase pipelin numer full mostli me-too product rova-t one compound
novel seem dead jak class high dose dead class minim
differenti categori compet face ever-increas brand generic/biosimilar
page
imbruvica import off-set humira could potenti unseat follow-on btk inhibitor
oncolog product clearli better data quickli displac older product azn head head
data late wolf comment later-gener btk inhibitor realli materi better
convinc data lack moment
outlook biggest market product collect total revenu
humira variou autoimmun disord world biggest drug reliabl
consist sourc growth year face uncertainti biosimilar enter
mavyret hcv abbv new improv hcv offer viekira rapid uptak
stun howev global sale may alreadi peak gaug rate declin
imbruvica variou b-cell malign lead asset pcyc acquisit big
product big growth expect continu monitor gener btk possibl threat
creon pancreat enzym replac therapi legaci specialti drug patent
protect gener yet unclear show
lupron variou hormone-rel disord treat endometriosi uterin fibroid
prostat cancer central precoci puberti face partial intra-portfolio cannib recently-
pipelin asset gener later-stag candid visibl higher includ
upadacitinib jak oral select inhibitor file ra psoriat arthriti crohn
diseas ulcer coliti atop dermat manag promis differenti jak profil vs pfe
xeljanz olumi assur dvt/pe profil issu one reason got
trip asset clearli within abbv domain expertis manag guid
ww sale model way especi dose like dead
best-in-class efficaci third entrant jak class serv indic heavi
brand increasingli gener competit
risankizumab file psoriasi clinic profil compar jnj tremfya guselkumab offer
conveni dose schedul vs anoth import late-stag asset fill humira
footstep manag guid ww sale model way entrant
class serv indic heavi brand increasingli gener competit
imbruvica btk indic expans true pipelin product per se approv cll mcl mzl
waldenstrom macroglobulinemia gvhd push earlier line treatment new tumor
type follicular lymphoma activ cll less activ outsid cll alreadi multi-billion-dollar
blockbust product good growth ahead far lead vs btk big downsid risk
page
gener btk azn acalabrutinib abl demonstr superior
consensu expect econom share
venclexta indic expans true pipelin product per se approv r/r cll
without del expans earlier line cll treatment tumor type aml mm
mcl partli live imbruvica shadow novel highli activ drug kol academ
center embrac drug fear pervad within commun set around drug safeti profil
low risk tumor lysi syndrom probabl deserv attent receiv today great opportun
broadli combin imbruvica one two punch econom share roch
rova-t stemcentrx acquisit treatment sclc triniti
sclc fail impress march irc orr irc dor month cross-trial
comparison basi look meaning better chemo furthermor taho sclc
halt meru mainten sclc continu expect re-bas recent
impair charg suggest may given rova-t complet
depatuxizumab mafodotin egfr product seem get much
attent pediatr gbm w/egfr amplif primari read began
page
valuat lowest group price-to-earnings full comp sheet see exhibit trade price-to-earnings
multipl ep ep ep use target
price-to-earnings multipl appli ep arriv year end price target use price target
multipl across cover compani rang
abbv incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
astrazeneca azn op pt long-term ep growth group averag plu
pipelin big china presenc take-out potenti
compani report factset wolf research price
page
wolf bullet-point view azn
investor sentiment gener attract azn futur growth prospect understand avers
extern feel like cook book
pipelin prowess thin higher-risk compound bace anifrolumab
occur still variou opportun phase commonli view major pipelin stori
histor great compani
binari event risk volatil roxadustat cardiovascular safeti data
upsid downsid
near-term outlook decent usher ep continu product sale growth
valuat expens near-term ep price-to-earnings normal out-year given superior growth prospect
net continu like azn best long-term grower group turn around
margin expans stori new growth come already-approv product
mean azn heavili depend futur pipelin traction unpredict said
azn still late-stag pipelin opportun ahead investor expect overli
high like two aspect azn footprint china vastli greater
compani could sourc long-term competit advantag potenti azn could one
day take-out target one smaller compani sector recal pfe attempt
announc organiz chang creat mirror commerci unit oncolog
biopharmaceut cvrm respiratori coincid departur sever senior execut
implement return growth mallon jallal sometim messili bohen
chmp recommend forziga dapagliflozin treatment adult patient
bodi mass limit repres ema attempt balanc posit clinic effect
reduct weight loss total daili insulin dose advers effect ketoacidosi small
next-gener rsv medicin receiv regulatori imprimatur fda btd
ema prime extern sanofi option particip us commerci opportun
part sobi synagi deal futur sourc extern incom
report solid quarter gave first-tim guidanc sustain product sale growth
ep increas detail see azn full postview result
guidanc relief lot catalyst best lt grower must-own
page
themi data cv prevent cad cv histori brilinta top-lin
posit could meaning data clean
import upcom event next
nsclc trialsneptun poseidon investor expect low especi
recent failur mystic os mean upsid downsid realli poseidon also
durva chemo chemo combo arm often over-look
addit lung cancer trial tumor type scchn sclc
bladder cancer role combo azn futur set tbd
combin avastin patient profound biomarker-select
competitor event prima ovarian monotherapi mainten hrd patient
competitor lynparza part tesaro acquisit
roxadustat anemia efficaci trial read await analysi cv safeti pool
analysi differ trial regulatori submiss end investor expect mix
partli checker histori compound anemia/epo/esa space also
commerci dynam dialysi market entrench competit pre-dialysi treatment market doesnt
calquenc cancer trial poor-risk cll elevate-tn r/r cll
head-to-head trial elevate-r/r abbv imbruvica r/r high risk cll earli
nccn alreadi recommend r/r cll clear us physician use alreadi indic
investor cautious optimist
themi cv prevent cad cv histori top-lin posit full result like
last origin mix parthenon lcm program could increas market
meaning result robust
noth materi think
page
best lt ep growth big pharma first sever year ep growth importantli
growth come newer base approv product word azn futur growth
heavili depend futur pipelin success difficult call
margin expans stori azn cost structur heavili out-of-whack follow period heavi patent
expiri burden expiri move background organ growth return due
variou import new product launch tagrisso farxiga imfinzi lynparza fasenra lead
natur margin expans substanti
heavi exposur oncolog one hottest diseas area azn exposur oncolog
nearli grow place concentr diseas area
second high-growth high-margin market segment cover compani
want increas exposur
heavi exposur china import em azn exposur china nearli
total product sale grow healthi double-digit level exposur peer group azn
say margin china similar margin europ despit sell price china
much lower exampl tagrisso price china lower us azn recent
struck deal gain coverag china nrdl
take-out potenti tri seem move big strateg mistak
get deal close view compani could still come knock howev
extern artifici ep boost stock even expens alreadi appear
practic sourc controversi sinc began manag wont say
time-frame ramp acknowledg peak ramp creat
tough comp given high profit dollar
margin expans alreadi bake doesnt deliv wolf comment admittedli margin
expans big pharma tend elus commonplac
mix qualiti pipelin failur could impact investor percept azn rebuild
pipelin stori alreadi bace anifrolumab met demis although compound
fail share price move much furthermor azn big bet io durvalumab tremelimumab
io/io combin seem increasingli unlik ever bear fruit
earlier-than-expect competit pacif small trial hoosier oncolog
group popul patient resembl pacif could theoret lead
nccn compendia list wolf comment would like recommend weak
one therefor enough make meaning differ
page
ceo pascal soriot leav press report look previous join teva
board initi formal search replac yet pascal assur go
outlook biggest market product collect total revenu
tagrisso cancer overtak symbicort azn largest drug especi import
asian market like japan china egfrmt nsclc patient found synerg well
azn market-lead china penetr small molecul drug royalti burden littl come
symbicort asthma/copd tail end life cycl face addit indirect
pressur gener us advair symbicort gener show model best guess
farxiga diabet one three franchis gener expect mid-
competit strong jardianc invokana recent declar cvot trial result
give small boost weaker lli empa though enabl hf indic eu
brilinta cv blockbust azn hope steadi grower final
themi may deliv second boost growth current analyst model
imfinzi cancer second pillar azn new oncolog imfinzi enter top
first time build strong launch develop market competit next
pipelin asset gener later-stag candid visibl higher includ
tagrisso anti-egfr tki mtegfr nsclc indic expans true pipelin drug per se
await matur os data flaura expect also run adjuv trial adaura
report investor given one much thought yet evid anti-
egfr tki yield benefit set less clear
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop merck alreadi approv ovarian cancer mani studi
set on-going predict good efficaci variou cancer brca mutat express
infrequ azn/mrk tri expand tumor brca limit combin
therapi exist medicin well pipelin product azn dna damag repair
ddr portfolio includ agent inhibitor atm inhibitor
azn claim commerci futur compound underestim
page
roxadustat oral hif-ph anemia azn us/china right complex three-way partnership
astella eu origin commerci futur partli depend whether show better
cardiovascular safeti demonstr pool result trial like olympu non-dialysi ckd
mace non-inferior vs placebo rocki dialysi ckd mace superior vs epogen investor
learn competit profil
tezepelumab anti-tslp mab asthma novel biolog block master regul asthma
inflamm pathway recd breakthrough therapi design data asthma suggest efficaci
regardless eo level holi grail excit mechan enter potenti crowd market
share econom trial run pathfind navig result
calquenc acalabrutinib btki mcl cll indic expans true pipelin drug per se
acerta acquisit go market leader imbruvica virtual
monopoli btki space azn hope differenti safeti three phase trial cll
earlier stage trial heme tumor
imfinzi tremelimumab main combo strategi azn io portfolio mystic os nsclc
recent fail os readout least mono durva trend in-lin pdx
deliv arm under-pow howev unclear imfinzi treme ever approv
pearl neptun poseidon studi data indic scchn bladder sclc
deck would enter io experienc market
anifrolumab failur first tulip trial sle lower expect tulip data expect
neg data second trial could last nail coffin
page
growth profil trough solid grower
valuat highest group full comp sheet see exhibit azn trade price-to-earnings multipl
ep ep ep use target price-to-earnings multipl
appli ep arriv year end price target use price target multipl
across cover compani rang
azn incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment given recent spate neg news io stock gutter sinc oct
sell capitul bmi celg inject new dimens uncertainti
mean
pipelin prowess pipelin thin becom much fuller celg term
internally-develop candid remain interest seem high risk
binari event risk ye relat io news flow competitor never-end sourc
news seem binari event risk celg revlimid patent also feed
near-term outlook financi result decent shape investor expect
opdivo overal clearli moder opdivo yervoy like continu disappoint
long-term outlook growth clearli correl trajectori opdivo beyond uncertainti
point big debat celg offset depend combin organ much
higher growth next sever year vs stand-alon follow sharp descent
due
valuat bmi impli price-to-earnings pro-forma celg estim put turn lower
net clearli controversi rate volatil
stock tie mishap immuno-oncolog space lost major lead
merck space continu controversi long-term trajectori opdivo
investor expect moder uncertainti price plausibl scenario opdivo
continu remain one two market lead therapi valu lung
think trial look opdivo yervoy part continu disappoint
chemo combo work would relief part data three
sourc long-term option upsid anti-pdx categori one whether product
work earlier stage adjuv cancer set data come time-frame
still far away celg struggl say like transact fundament basi
timeand despit variou sourc genuin controversi still think share like deliv
decent return current level pro-forma valuat still possibl albeit low
odd anoth compani come acquir celg deal close
celg acquisit celg share one share cash cvr initi
view acquisit see initi impress celg deal import
long-term issu valuat emb uncertainti alreadi
bear-cas point manag need address complet one bull case point
recent field investor survey see bmy-celg investor sentiment survey
page
announc ema approv opdivo low dose yervoy rcc intermediate/poor risk
patient eu base come ema chmp recommend
combo juli
report result in-lin revenu beat ep announc guidanc
in-lin expect detail see full postview
earn opdivo sl weaker guidanc ok buy controversi
announc withdraw us regulatori applic opdivo low
dose yervoy nsclc patient discuss w/ fda
present asco-gu show keytruda plu inlyta improv os orr
compar sutent data also seem compar favor still think
opdivo yervoy home see implic rcc
import upcom event gener next
chemo cycl assum base regimen
like fail lung matter concoct
combo rcc could help level play field
adjuv readout opdivo yervoy melanoma opdivo mono bladder
opdivo mono esophag
luspatercept celg asset fda file expect md beta-thalassemia
approv
ozanimod celg asset fda submiss refractori mm expect march
fedratinib celg asset fda approv myelofibrosi end
ipr patent challeng eliqui made recent progress eliqui ip litig
appar settlement januari remov overhang ipr patent
expir district court side trial expect begin follow
page
unfavor markman hear court adopt defend claim
celg deal closur guidanc
mayb pend celg deal catalyz someon take w/o celg one smaller
revenu base would easier digest bring one two market-lead seem
theoret bidder make sens given commentari compani result
celg bring much fuller phase pipelin provid near-term catalyst long-term
revenu stream mani repres novel cutting-edg scienc
still formid player io lung combin continu look iffi
opdivo use combin chemotherapi yield posit result product alreadi
commerci momentum stellar chemo combo data
requir result need respect label enabl
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers
industri final succeed find synergist agent combin anti-pdx therapi make
greater proport patient respons therapi admittedli lot disappoint
date front
valuat low despit controversi bmi low price-to-earnings multipl best goe
realli low pro-forma ep w/celg
celg deal portend big problem opdivo bmi confid opdivo shaken ahead
read-out could go ex-growth manag guid continu opdivo growth
given guidanc beyond uber-bear case opdivo
mechanist flaw drug rel keytruda
celg magnifi bmi exist long-term patent cliff exposur revlimid celg
eliqui opdivo start
page
revlimid uncertainti term time addit gener entrant earli at-risk launch undermin
valu deal diminish cash flow argument bring forward cliff
disproportion sensit potenti us healthcar reform due product mix
among highest exposur coverag program like medicare/medicaid meaning
reform program ep could disproportion hit
take-out thesi evapor post celg-deal closur
outlook biggest market product collect total revenu
eliqui stroke/dvt market-lead oral anti-coagul split growth
continu linearli displac warfarin target undiagnos untreat popul off-pat
opdivo cancer formerli market-lead recent surpass keytruda
maintain growth long-term may depend indic outsid nsclc off-pat
time-frame
yervoy cancer approv azn may never see light day
mayb smart divest growth depend expans opdivo yervoy combo
indic lower dose shown accept toxic still deliv efficaci
sprycel leukemia matur product expect enter ex-growth phase near-term
gener possibl enter ex-u soon indirect pressur gener gleevec/imantinib us
orencia autoimmun diseas matur product still grow crowd arthriti
market clear biosimilar competit sight
pipelin asset gener later-stag candid visibl higher includ
anti-bcma car-t celg registr karmma studi refractori mm fulli enrol
potenti us approv bcma hot target mm multipl compani leverag
differ modal may easier use real world cell therapi
opdivo yervoy indic expans true pipelin drug per se opdivo
approv mel nsclc rcc hodgkin scchn msi-h bladder variou trial
on-going host tumor type term combin approv mel
rcc studi tumor type well import nsclc
page
inh recent start psoriasi result data
decent category-lead key oral therapi versu newer approv agent
inject crowd space earlier phase evalu underway includ lupu ibd
luspatercept erythroid matur agent anemia celg phase trial md post epo
beta-thalassemia transfus depend read posit file expect
myelofibrosi phase small imbal thromboembol event seen betal-th trial overal
fairli derisk point
liso-cel car-t celg us file rrdlbcl expect approv
registr trial cll recent start therapi alreadi competit yescarta
kymriah market although liso-cel data seem stronger paper
ozanimod rrm ibd celg fda refus file rrm earli due
insuffici nonclin clinic pharmacolog data refil expect complet
non-clin pk/pd bridg studi look major activ metabolit ad com seem possibl
phase ibd trial uc crohn on-going
program evalu tumor phase trial combin opdivo start melanoma
data phase trial recent started/plan rcc bladder nsclc
still other design sclc tnbc gastric sarcoma phase data
recent asco-gu shook investor confid asset
relatlimab phase trial combin opdivo mel data phase data
shown signal terribl strong one view
fedratinib inh celg file myelofibrosi patient relaps ruxolitinib jakifi
phase polycythaemia vera ongiong previous shelv sanofi safeti concern celg
acquir impact biomedicin reviv program
variou earlier-stag i/o drug human studi anti-kir anti-gitr other
difficult ascrib valu mani earlier stage asset given human data
publish date gener slow progress across industri next gen io agent either
monotherapi combin
page
growth profil exclud celg decent toggl opdivo trajectori
uncertain
valuat current price-to-earnings among lowest stand-alon basi full comp sheet see exhibit
trade price-to-earnings multipl ep ep
ep use target price-to-earnings multipl appli ep arriv year end price
target use price target multipl across cover compani rang
bmi incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
pp pt solid grower increment posit
compani report factset wolf research price
page
wolf bullet-point view
pipelin prowess histor one better organ late-stag pipelin
interest opportun promis tirzepatid
binari event risk event monitor tanezumab remain iffi market expect mix
need see novo price oral semaglutid dose titrat data tirzepatid
near-term outlook assum new guidanc right weather headwind
cialis/forteo better initi expect polit insulin remain target could put
cross-hair hard us see materi risk downsid
long-term outlook solid one best long-term growth rate
valuat among highest group
net come long way last sever year upgrad stock
heavili favor pendulum clearli swung stock consensu
buy re-launch wolf late peer-perform rate feel
risk reward evenli balanc strong run throughout year howev back
guidanc given decemb analyst day long-term outlook admittedli seem better
initi model leav well-posit compani still substanti exposur diabet
revenu categori seem well posit rel peer also categori
price competit meaning look opportun construct
announc acquisit loxo oncolog approx deal complet
announc failur confirmatori announc trial lartruvo soft tissu sarcoma due
lack clinic benefit fda ema subsequ recommend new patient start
lartruvo
announc posit top-line result trial baricitinib
moderate-to-sever atop dermat addit phase trial report
result higher revenu in-lin ep guidanc lower anticip
loxo lartruvo detail see full postview in-lin ep
announc initi exchang offer divest remain interest elanco
page
announc mix top-line result phase tango trial tanezumab chronic low back
pain dose posit statist signific dose statist
signific entir surpris given sever debilit clbp rpoa rate also
higher treatment group unusu given comorbid oa patient exclud
trial third phase trial tanezumab last long-term safeti studi expect
file
import upcom event next
trulic rewind cv toplin posit full data present june adal seem excit
tanezumab ngf read-out long-term oa safeti trial studi need file
tirzepatid releas dose titrat data ada
lasmiditan readout posit acut migrain recent submit fda mean
pegilodecakin trial nsclc pegliodecakin keytruda readout
trial nsclc pegliodecakin opdivo readout
ret inhibitor phase studi nsclc thyroid cancer readout
potenti initi submiss
competitor event approv novonordisk oral semaglutid competitor trulic
beyond assess competit label drug price import datapoint watch
assum price somewher current brand oral inject like us
enbrel biosimilar patent litig septemb court rule expect earli outcom
favor sandoz erelzi could launch earlier expect would sudden/unexpect
competit pressur product includ taltz off-the-radar risk visibl slowli rise
collect growth driver recently-approv still pipelin small
revenu base includ olumiant/baricitinib lasmiditan galcanezumab tanezumab alzheim
eventuallyor mayb never may also launch new lli smaller
page
revenu base vs peer often almost give compani greater earn
margin expans stori deliv commit long-term spend target first
given say margin expans go forward
tirzepatid give long-term protect diabet franchis given
could multi-year lead competitor blood sugar control weight loss data category-lead
success would truli transform would send share straight noth stock
price perfect current level expens rel growth like deliv least
lli diabet exposur liabil three differ front
price fierc price competit categori lli current overal exposur high total
compani sale even elanco divest
polit insulin price spotlight may stay way insulin account
sale humalog alon account mayb fda use insulin first opportun
brand competit trulic face competit novonordisk oral semaglutid could
launch possibl price strategi remain unknown categori growth
high enough support multipl product trulic could still feel impact depend sema
clinic profil price gip/glp doesnt launch compani guidanc may
protect franchis anytim soon
high expect tirzepatid high potenti singl
trial shorter durat underli biolog well understood also anti-drug antibodi ada
quit high
tanezumab set disappoint lly/pf seem semi cautiou describ safeti hurdl
yet cross commerci case may prove elus partli opioid crisi someth
seem exist us
page
outlook biggest market product collect total revenu
trulic diabet one two market-lead franchis strong growth prospect
degre risk oral
humalog diabet tail end life-cycl begin face biosimilar us/eu
alimta cancer matur product grow much even increas usag
conjunct pdx eu alreadi face gener us gener
taltz pso fourth year launch ramp pso potenti addit
indic expans axspa
forteo osteoporosi tail end life-cycl possibl face first biosimilar competit
pipelin asset gener later-stag candid visibl higher includ
dual incretin agonist diabet suddenli high expect
product stem placebo- active-compar random control data
look great better blood sugar control better weight loss toler moder wors
say dose titrat reduc investor keep mind howev singl
phase dose-rang trial launch phase trial mind anti-drug antibodi
ada potenti neutral drug clinic effect given structur homolog
ret inhibitor cancer first-in-class ret inhibitor lli acquisit loxo januari
breakthrough therapi design ret-fus posit nsclc thyroid cancer ret-mut
medullari thyroid cancer phase studi nsclc read potenti earli
submiss late
tanezumab anti-ngf pain novel non-opioid mechan sever pain partial clinic hold lift
indic osteoarthr chronic lower back pain first three studi studi
tango posit still need readout safeti studi better defin rpoa signal
higher rpoa signal tango chronic lower back pain concern sinc comorbid oa patient
lasmiditan acut migrain non-triptan oral therapi avoid vasoconstrict seem
caus dizzi paresthesia interest oral therapi acut attack
complement cgrp antagonist
page
pegilodecakin cancer pegyl came armo
acquisit drug alreadi variou phase trial purportedli singl agent
activ first phase read sequoia pancreat cancer pegliodecakin folfox readout
alzheim past failur solanezumab lanabecestat virtual everi compani
keep investor expect disease-modifi drug alzheim low scienc slowli
progress lli focu a-beta specif antibodi antibodi anti-tau antibodi
combo broadest ad platform compani
growth profil steadi growth continu margin expans
valuat second highest price-to-earnings multipl group full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target use
price target multipl across cover compani rang
lli incom statement revenu forecast balanc sheet/cash flow statement see appendix financi
statement end report
page
glaxosmithklin gsk pp pt definit shake thing futur split
consum someth look forward near-term bit sleepi still
compani report factset wolf research price
page
wolf bullet-point view gsk
investor sentiment mix point view
pipelin prowess thinner side term late-stag product raw abil
total devoid bcma recent merck kgaa gsk promis turn
around new leadership step right direct
binari event risk medium degre bcma data xejula data
near-term outlook stock volatil back tsro acquisit caus sell-off
consum jv format led share price rebound seem like quieter partli
much way catalyst ep growth neg due us advair gx
tsro dilut trough hiv uncertainti remain due competit script trend need
long-term outlook steadier ep growth trajectori
valuat price-to-earnings lower end peer group averag
net current level gsk face limit downsid risk pipelin thin
total devoid growth profil modest compani activ tri chang thing
win plaudit old new approach recent exampl includ commit
split newly-form consum health far away effect meaning chang
big organ like gsk easi histori show often fall flat patient value-ori
investor gsk may make sens especi dividend yield everyon els stori may
yet feel ripe enough hiv competit threat possibl chang payer dynam need
monitor gsk abl weather
chairman sir philip hampton step time open board search successor
chairman hampton oversaw manag transit walmsley new broom sweep senior
leader successor lead compani toward pharma chc split
gener advair final launch discount day later gsk launch
author gener expect sandoz line next end hikma teva
gsk partner mrk gr develop/commerci fusion mileston
payment tie success nsclc data keytruda interest
product small patient number
page
report result ahead revenu ep first-tim guidanc slightli
weaker ep declin well understood detail see global pharmaceut gsk full
import upcom event next
bcma antibodi drug conjug pivot trial readout triple-
zejula parpi prima ovarian mainten hrd patient competitor azn/mrk
lynparza also mainten trial time frame key design differ howev part
dolutegravir/lamivudin hiv import dolutegravi regimen larger
treatment-nav set recent file prioriti review voucher fda decis
cabotegravir hiv await week dose phase trial cabotegravir rilpivirin
regulatori submiss base flair atla
fostemsavir hiv regulatori submiss treatment-experienc hiv posit toplin
manufactur led delay lead compound among hiv asset acquir
anti-gm-csf recent present posit phase data acr gsk plan initi
chc jv format anticip end contemporan close horlick consum
nutrit divest sharehold circular show profit new asset spin
per management guidanc wolf comment save earli spin raini day
tsempano safeti updat dolutegravir small trial africa tsempano studi show
neural tube defect pregnant women dtg led label warn us geographi
receiv littl attent follow analysi report addit case due mar/april
time-frame radar risk investor
bull case gsk risk upsid
sum-of-the-part basi gsk attract larger exposur consum health
sale follow jv consumm appli compar price-to-earnings busi
page
use consum compani comp show impli price-to-earnings multipl gsk pharma busi
ceo chang thing made lot outsid hire think luke miel barron kevin sin iain
mackay done one acquisit tsro commit eventu spin consum health
creat hope trade demonstr proactiv manag team noth els sharehold
dividend yield higher group averag
valuat low toward low end peer group rang histor rarer gsk
c-suit execut without pharma background newer ceo emma walmsley light
pharma/vaccin experi clearli core profit driver gsk new cfo iain mackay likewis
pharma background join hsbc
turn around tall order especi new head live far away
gsk respect new head resid sf bay area long way stevenag uk
pennsylvania us gsk late-stag pipelin thinner side question remain
commerci opportun lead asset anti-bcma
balanc sheet constrain gsk balance-sheet constrain lock high dividend
pay-out abil way bring new franchis new asset limit esp post
variou threat hiv/aid franchis total sale key growth driver
threat includ gild biktarvi bictegravir taf direct competit gsk tivicay/triumeq
take share gsk defens so-cal two-drug regimen weak
one may fear resist us payer dynam may chang chang
protect drug class statu one chang cap price increas tsempano studi
follow-up clearli answer question neural-tub defect off-the-radar risk downsid
could competit disadvantag dolutegravir
suppli limit shingrix gsk say curtail growth new suppli open difficult
know analyst model correctli
outlook biggest market product collect gbp total
advair asthma/copd declin product final experienc first us gener entri
acceler declin even faster
page
relvar/breo asthma/copd slow grower near mid-term crowd respiratori
triumeq growth slow near term gilead biktarvi continu pose
tivicay remain decent grower near mid-term continu face risk
gilead biktarvi
shingrix shingl vaccin new vaccin well whose efficaci blow
competit merck zostavax away suppli limit nearer-term
pipelin asset gener later-stag candid visibl higher includ
bcma antibodi drug conjug multipl myeloma lead way term drug-
base anti-bcma approach car-t bcma fusion
chase phase data gsk drug impress show orr patient tripl
refractori proteasom inhibitors/ immunomodulators/ daratuzumab pivot trial data
patient triple-refractori larg program combin trial report trial
start would gsk first meaning cancer medicin almost exit area
us breakthrough therapi design award data
co-develop/co-commerci mrk gr interest compound
appar better orr pdx small uncontrol trial thu far collabor gate on-
daprodustat hif-prolyl hydroxylas inhibitor anemia oral agent meant displac inject
epo/esa product similar azn roxadustat safeti data phase trial ascend-d
dialysi readout ascend-n non-dialysi readout
cabotegravir long-act integras inhibitor hiv treatment possibl prevent
hiv/aid gsk believ patient want everi two-month inject versu daili oral cite
trial proof-of-principl confirmatori flair treatment-nav atla treatment-
experienc posit present extend dose week
launch gsk also pursu prevent high risk individu would quit novel
unclear realist phase trial compar inject cabotegravir gild truvada
at-risk men second phase trial women start launch well downstream
fostemsavir attach inhibitor acquisit bmi hiv asset first-in-class drug
treatment-experienc hiv smaller commerci indic phase bright studi recent
toplin posit transfer manufactur delay regulatori submiss
page
anti-gm-csf ra fulli human antibodi compet crowd ra space
effect associ pain licens morphosi primari endpoint phase trial
statist signific present acr gsk plan advanc phase compar xeljanz
cite pain relief ra crowd increasingli gener
growth profil trough return growth thereaft reason
valuat current price-to-earnings multipl lower end full comp sheet see exhibit gsk trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target use
price target multipl across cover compani rang
gsk incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
merck op pt longer keytruda stori valuat still reason growth
deliv next year
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment morph consensu buy keytruda almost singular
pipelin prowess late-stag pipelin remain thin histor good core
compet deserv credit nearli flawless execut io continu outpac
binari event risk lower end mostli tie variou io trial readout remain
biggest competitor monitor like stay posit investor often forget azn
near-term outlook ep growth look competit bias upsid keytruda grow
faster expect also gardasil under-model near- long-term opportun
long-term outlook long-term outlook solidifi nice one stock
coverag capabl post doubl digit ep growth sever driver keytruda gardasil lynparza
possibl lenvima
valuat modestli averag price-to-earnings multipl basi
net becom consensu buy valuat still reason
given above-averag growth profil compar low event risk fulli expect
remain io compani addit driver io upsid one form
adjuv trial could push anti-pdx therapi earlier line usag percept
one growth driver keytruda incorrect view gardasil second major
futur growth driver think consensu under-model tune sever billion dollar
written recent furthermor patent cliff product like
meaning competit threat horizon mrk biggest challeng simpli keep
demand also claim lynparza azn lenvima eisai under-
appreci realli need round stori late-stag pipelin thin
moment solv problem predict reli vari degre
receiv breakthrough therapi design btd fda prevent invas
pneumococc diseas infant children adolesc
report earn earn ep in-lin consensu revenu
ep guidanc slightli weaker end compar consensu estim announc
analyst day june detail see full postview in-lin result guidanc slightli
weak ok decent grower sever year
page
present asco-gu show improv os orr compar
sutent data also seem compar favor fda also grant prioriti review
rcc day earlier detail see implic rcc
receiv fda approv keytruda adjuv treatment melanoma involv lymph
node follow complet resect base show reduct diseas recurr death
compar placebo
announc miss os co-primari endpoint compar placebo
unclear affect keytruda current condit approv base like
announc acquisit immun design clinic stage immunotherapi vaccin
compani base glaa zvex technolog platform
import upcom event next
keytruda/io indic expans competitor read-out
approv nsclc april june sclc
june rcc june
competitor read-out main threat part look os
patient part chemo combo two cycl chemo opdivo yervoy
also azn poseidon trial look durva treme chemo durva chemo
ovarian bevacizumab combo regardless brca statu hrrmt mcrpc profound
competitor event prima ovarian monotherapi mainten hrd patient
competitor lynparza part tesaro acquisit
prevnar follow-on two phase adult trial read pediatr trial read
page
lenvima tki rcc combo keytruda read-out
june analyst day first long time predict talk variou base busi driver
well effort
 would fill pipelin thin context shrink base said
transform deal tabl essenti defin tie-up w/ anoth larg pharma co
impli option tabl could still deal ten billion dollar
three long-term sourc io categori upsid would benefit two market leader
disproportion three long-term sourc import upsid io categori
mind adjuv opportun anti-pdx therapi get use earlier-stag diseas
would translat even bigger difficult quantifi market opportun potenti under-
model ex-u anti-pdx opportun base histor preced meaning cancer drug
usual sell outsid us us consensu current model revers
industri final succeed find synergist agent combin anti-pdx therapi make
greater proport patient respons therapi admittedli lot disappoint
date front
major gardasil upsid still substanti under-model old vaccin see renew life
move beyond std vaccin prevent hpv cancer vaccin also roll new
geographi china major driver gain broader label higher age rang gender
neutral near monopoli gsk product round error competit en
rout smaller em compani vaccin dont face gener competit think consensu
could underestim sale even beyond last three
month step gardasil estim unabl satisfi demand
billion dollar
suddenli one better ep grower doubl digit ep growth averag januvia us
loe single-year blip model
valuat fair rel growth prospect lower event risk
consensu buy keytruda opportun fulli built risk downsid competitor gain
traction opdivo yervoy wolf comment odd good data particular
combo low view azn durva treme
page
io growth driver heavi eros elsewher mrk big base sever franchis
face face commerci pressur either brand loss exclus includ
januvia price risk competit loe start remicad biosimilar zetia/vytorin
loe zostavax gsk wolf comment ignor upsid gardasil/lynparza/lenvima
old use great dead simpli luck bought
sgp similarli sgp luck bought organon wit thin late-stag
pipelin despit spend variou setback last mani year apart
keytruda rare use fail trial
outlook biggest market product collect total revenu
keytruda cancer market-lead put pole posit within competit
lucr io market bmi opdivo still viabl alreadi blockbust we/consensu
expect drug doubl size off-pat time-frame
januvia/janumet diabet mrk biggest product keytruda class-lead
inhibitor matur brand face price pressur mount competit oral
therapi sale hold steadi despit
gardasil hpv lead hpv vaccin gsk cervarix nearli round error
futur growth fuel china approv expans older popul also male demand
outstrip suppli work hard increas optim exist footprint
addit new product line gener risk never
isentress hiv old legaci integras inhibitor ex-growth due competit
newer oral agent pressur gsk off-pat
bridion anesthet surgic anesthesia drug come schering-
plough acquisit seen sharp acceler recent year off-pat
pipelin asset gener later-stag candid visibl higher includ
keytruda approv alreadi variou cancer indic expans true pipelin
drug per se alreadi approv ten tumor type way kidney breast crucial driver
futur compani growth expect high on-going success execut thu far
lynparza parp variou cancer indic expans true pipelin drug per se lynparza
co-develop azn alreadi approv ovarian cancer mani studi
set on-going predict good efficaci variou cancer brca mutat express
page
infrequ azn/mrk tri expand tumor brca limit combin
therapi exist medicin well pipelin product azn claim commerci
futur compound underestim
lenvima multi-kinas inhibitor approv alreadi variou cancer indic expans true
pipelin drug per se new compound came deal eisai easi
overlook given book share revenu net commerci expens allianc
revenu approv thyroid cancer rcc addit on-going combo effort
rcc agreement call combin studi differ tumor type
endometri cancer non-smal cell lung cancer hepatocellular carcinoma head neck cancer bladder
cancer melanoma efficaci compel thu far think investor under-estim
pneumococc conjug vaccin next-gen vaccin evalu adult
pediatr offer two addit serotyp protect pfe class-lead two
phase adult trial read pediatr trial read howev next-gen
vaccin valent also work call question long-term relev mrk product
least adult less year ahead also on-going patent battl
gefapix chronic cough theoret larg patient popul radar
investor seem toler issu dysgeusia recent start highlight
asset frequenc overal pipelin thin concern aris
payer coverag first two chronic cough read
vericiguat sgc partner bayer advanc reduc eject fraction heart failur hfref
despit mix result read-out schedul seem get littl air time
variou earlier-stag io asset either wholly-own partner sting gitr
rig-i cavatak lot support data far compani
page
growth profil consist solid top- bottom-lin grower
januvia us loe clip growth growth return
valuat current price-to-earnings multipl modestli averag full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep
use target price-to-earnings multipl appli ep arriv year end price target
use price target multipl across cover compani rang
mrk incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
compani report wolf research price
page
wolf bullet-point view novn
investor sentiment steadili turn coincid va take ceo
pipelin prowess abil solid afraid cut edg current late-stag
pipelin full sever compound larg de-risk
near-term outlook good growth catalyst ahead keep investor engag
long-term outlook reason grower variou creat headwind
valuat modestli averag
net like novarti one easier stori tell identifi top
pick start surprisingli favor sentiment steadili warm
full pipelin compar low risk profil reason growth new ceo va narasimhan
execut quarterli perform sinc take februari investor like one rare
ceo hail therefor abl talk detail pipelin catalyst ahead includ
continu narrow focu alcon spin-out occasion rumbl get rid sandoz variou
pipelin approvals/launch entresto track well becom mani billion dollar product investor
alway hope jnj eclips trial come gone elimin overhang long-term
growth reason great due variou futur perhap novarti final becom
aggress take cost system way boost ep may mere pipe dream
announc fda grant breakthrough therapi design crizanlizumab
prevent vaso-occlus crise sickl cell diseas
report revenu in-lin ep slightli gave first-tim guidanc two-way
current group structur new focus medicin compani ex-alcon ex-sandoz us
quarter guidanc almost in-lin promis margin expans continu
icer publish preliminari report say cost effect sma type price
icer prepar shock see novarti actual set price
import upcom event next
page
siponimod us approv secondari progress ms spm
label read novarti previous guid us get data label offici
indic per se contrast eu guid offici spm indic brand name mayzent
sma gene therapi may fda approv decis expect one-tim gene therapi
treatment sma type approv japan eu expect strong trial sma
type present may brand name zolgensma
crizanlizumab fda eu file prevent vaso-occlus crisi voc
ofatumumab asclepio ii relaps refractori ms read-out moa
rog ocrevu interestingli novarti go ppm reason never fulli
clear us segment one competitor rog ocrevu licens genmab
entresto indic expans paragon-hf hfpef final analysi read-out free
call option upsid could expand treatabl popul substanti ad peak
vegf late approv wet
alpelisib potenti us approv mt hr breast cancer
fevipipr aka antagonist potenti read-out interim result
phase trial asthma final
enbrel biosimilar patent litig septemb court rule expect earli outcom
favor sandoz erelzi could launch earlier expect would sudden/unexpect
competit pressur product includ cosentyx off-the-radar risk visibl slowli rise
alcon tax-fre spin-off new public compani eye care
one fullest late-stag pipelin group kymriah siponimod
mani larg de-risk given trial alreadi report posit
entresto problem fix sit front upsid strong endors
esc treatment guidelin put product on-track becom mega-blockbust investor
origin hope pioneer-hf help expand acut patient paragon-hf
page
patent cliff kick road one bear case point novn
heavi gener exposur come gilenya loe follow earlier
ptab rule gener like delay perhap coupl year certain
delay gener entri would also commerci benefit novn ms pipelin drug siponimod
ofatumumab remov price gap gilenya wolf comment afinitor exjad
still face gener
binari event risk major exposur diseas area signific price competit
loom court case binari clinic trial read-out expect high
ramp faster expect patient pool limit size parent may still beat
door new therapi one toggl price novarti said product cost-
effect price point wolf comment consensu model product hit
market time-frame realiti payment model may amort payment
longer period time
va big cost cutter hope descript futur margin expans allud
big cost cut program someth heretofor achiev predecessor ceo
growth great despit compel stori long-term ep growth averag
gilenya gener inde still come even though ipr rule novn
favor gener could still theoret launch risk major analyst assum entri
later could put ep forecast risk
cosentyx destin eventu becom novn biggest product face competit
environ specif could threaten durabl cosentyx lead
base primarili less frequent inject slightli better efficaci farther novel moa
bmi inhibitor oral enbrel litig describ upcom event section
addit risk top
manag consist over-promis under-deliv dna unfortun
outlook biggest market product collect total revenu
gilenya multipl sclerosi first-in-class modul relapsing/remit ms us
patent situat remain flux juli ipr win novn favor delay gener entri
novn gener form siponimod posit differ
segment market spm recent label chang sever disabl post-discontinu could potenti
discourag physician prescrib gilenya new patient
page
cosentyx psoriasi autoimmun disord first-in-class
becom novn largest product face increasingli crowd market biolog small
lucenti amd/dm partner novn ex-u right vegf inhibitor
variou ophthalmolog indic struggl sinc bay/regn compet vegf eylea enter market
patient-friendli dose schedul vs better perceiv efficaci protocol
novn expect return favor look like better product uncertain loe time
model best guess
diovan franchis hypertens legaci blockbust hypertens drug sinc
gone gener still remain one novn largest product today gradual declin
tasigna cml successor gleevec basic flat sinc gleevec went gener
pipelin asset gener later-stag candid visibl higher includ
sma gene therapi potenti one-tim cur gene therapi sma type work
replac gene produc function smn protein vs biogen spinraza splice modul
improv smn protein product via less effect pathway
kymriah car-t indic expans true pipelin product per se alreadi approv
pediatr r/r dlbcl seek expans hematolog malign fl cll
cutting-edg scienc commerci model remain hurdl
vegf trial wet alreadi read-out demonstr function non-inferior
superior sever anatom measur efficaci vs regn eylea offer less frequent dose
vs eylea decent valu proposit market novn know well due lucenti
run entrench incumb biosimilar lucenti perhap exact time
biosimilar unclear importantli product bring novn us revenu stream first time
siponimod file secondari progress ms spm would repres first specif patient
popul therapi current approv label key anoth market novn know
well due gilenya
fevipipr three asthma trial spirit on-going oral
receptor antagonist moder sever asthma interim result expect readout
spirit final result includ expect novn
claim fevipipr show similar efficaci reduct exacerb sputum eosinophil compar
biolog studi conveni oral dose describ potenti patient popul
page
around base posit zeal luster result novn also studi fevipipr
indic includ nasal polyposi copd allerg rhiniti
vs month orr vs patient mutat breast
cancer compar fulvestr alon toler problem mutat repres
hr /her- patient segment approxim breast cancer patient benefit
patient lack mutat overal surviv result matur also program taselisib
kill novn plod
entresto arb/nep indic expans true pipelin product per se alreadi approv
hfref seek expans hfpef popul paragon-hf interim analysi done
aug trial continu schedul complet around expect specif
popul low given long list prior hfpef failur would meaning upsid work
approv therapi
selexi acquisit file posit data sustain sickl
cell pain crisi area high unmet need get lot investor attent could bigger
opportun expect potenti rare diseas might think
ofatumumab genmab relaps remit ms complement siponimod
spm build novn ms presenc gilenya often ignor given time-lag behind rog
ocrevu kill oddli develop ppm ocrevu label
canakinumab alreadi approv brand name ilari rare auto-immun disord
seek approv cv-risk reduct high crp patient base canto trial howev receiv
oct jeopard futur viabil product anoth issu product
goe loe drug impact lung cancer also studi base surpris find
canto lung cancer mortal lower result
page
growth profil moder loe drag growth
valuat current price-to-earnings multipl averag full comp sheet see exhibit novn trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target
use price target multipl across cover compani rang
novn incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
pp pt pipelin growth still flattish next coupl year
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment gener support rare top pick
pipelin prowess abil histor weak phase pipelin arguabl look
better tafamidi perhap tangibl excit new product point
binari event risk noth signific call near-term ibranc adjuv read-out like later
far away still
near-term outlook ep growth flattish fairli quiet stori
long-term outlook ep growth rebound post moder level
valuat price-to-earnings multipl lower end group averagea often
net pfe pipelin improv growth next two year remain flattish
share expens new leadership announc
anyth chang substant probabl alreadi gone variou iter
restructur final piec dispos consum recent fell place format
jv gsk given long-term growth modest stori catalyst-lit even
better pipelin difficult see stock outperform defens rotat could
increment buyer low valuat offer downsid support
discontinu javelin ovarian trial base idmc recommend interim analysi
achiev ep javelin ovarian parp earlier phase studi avelumab combo studi
still on-go
fda accept nda tafamidi transthyretin amyloid cardiomyopathi attr-cm
announc tanezumab oa trial show treatment arm met co-primari ep
arm met two result show higher rpoa vs placebo reaffirm cautiou view
regulatory/commerci viabil
report earn revenu ep in-lin consensu revenu
ep guid consensu due account adjust income/deduct
start detail see full postview decent guidanc expect
fda accept sbla prioriti review bavencio plu inlyta line advanc rcc base
javelin renal data doesnt look good mrk
page
announc posit arch result show xtandi plu reduc risk radiograph
progress death vs alon metastat hormon sensit prostat cancer mhspc
announc tanezumab clbp trial show dose met primari endpoint pain
improv dose rpoa observ treat patient vs placebo
group somewhat concern rpoa also seen clbp patient isol oa
announc xeljanz post-market studi look bid significantli pulmonari
embol overal mortal compar bid tnfi arm activ transit
patient high dose low dose implic overal jak class safeti percept
european commiss approv zirabev biosimilar avastin zirabev pfe biosimilar
approv europ
import upcom event next
tanezumab ngf read-out long-term oa safeti trial studi need file
tafamidi ttr stabil regulatori decis ttr-cardiomyopathi
rivipansel pan-selectin result sickl cell pain crise
first four moderate-to-sever atop dermat jade
read jade
bavencio mono nsclc javelin lung read-out rcc
noth major note
pipelin turn new leaf final get return invest
intern pipelin traction made varieti diseas area
page
gener lot cash provid flexibl buy solut intern effort stall also return cash
sharehold via dividend buyback like depend done past
cheap despit stock run summer still rel cheap forward price-to-earnings basi
compar peer
better pipelin still enough move ep meaning although pipelin
mani asset late-to-market undifferenti interest one tafamidi
rivipansel still hurdl clear either commerci clinic pfe long-term ep growth remain
ibranc forecast risk ibranc sold ww consensu expect
growth us sale y/i script start plateau impli phase adjuv
trial need hit analyst forecast met yet recent neoadjuv pallet studi result
show improv biomark clinic respons seen furthermor competitor
space novn continu nip ibranc heel
growth anytim soon driven lyrica go loe mid-year result flat ep vs
creat one hurdl out-performance
split-up big tabl what next manag comment taken
face valu less interest stori take away option mean perform boil
pfe base busi hard see inflect point pipelin
outlook biggest market product collect total revenu
pediatr adult pneumococc diseas virtual monopoli
perform flattish matur could potenti threat vaccin
yet convinc recent move phase defend franchis move
vaccin phase soon natur meaning long appropri
immunogen achiev similar
lyrica pain tail end product life-cycl goe loe mid becom
drag growth
ibranc breast cancer origin monopoli face soft competit
novn direct competitor like still retain domin lead time
advantag growth slowli moder due high penetr adjuv trial would provid next leg
growth palla penelope-b trial report success guarante
page
enbrel ra auto-immun diseas eu declin due biosimilar
thu drag growth
lipitor cholesterol ye still make top list even patent
sever year mani geographi hold steadi em account
pipelin asset gener later-stag candid visibl higher includ
ibranc indic expans true pipelin product per se alreadi approv
advanc metastat breast cancer seek expans earlier line treatment
adjuv trial penelope-b palla arent slate read-out late posit
outcom what requir meet analyst lofti sale expect phase neoadjuv
pallet studi result show improv biomark clinic respons seen
tafamidi ttr stabil file ttr-cardiomyopathi follow strongli posit result attr-act
hard endpoint all-caus mortal drug mix past approv eu ttr-
polyneuropathi fail gain approv us like slow
tanezumab anti-ngf pain novel non-opioid mechan sever pain partial clinic hold lift
indic osteoarthr chronic lower back pain first three studi studi
tango posit still need readout safeti studi better defin rpoa signal
higher rpoa signal tango chronic lower back pain concern sinc comorbid oa patient
oral inhibitor atop dermat phase data gener breakthrough
therapi design btd fda four phase trial on-going first one due report around
follow-on prevnar initi develop adult receiv breakthrough
therapi design phase data say move phase around year-end
unclear develop plan pediatr presum work
competit respons mrk vaccin phase less year ahead
least adult
rivipansel pan-selectin sickl cell diseas follow encourag result demonstr
trend toward quicker resolut pain crise area high unmet need compet novn
iv rivipansel oral similar market entri time read-out like
growth profil sleepi grower mid-term absorb hit lyrica
us loe invest behind sever new product launch modest commerci opportun
page
valuat current price-to-earnings toward low end group full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep
use target price-to-earnings multipl appli ep arriv year end price target
use price target multipl across cover compani rang
pfe incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
roch pp pt chf pipelin best-in-class biosimilar cast long shadow
compani report factset wolf research price
page
wolf bullet-point view
investor sentiment mix view skew posit recent month tug-of-war
pipelin bull align biosimilar risk bear align
pipelin prowess best-in-class compani pipelin continu get even
interest oncolog non-oncolog area
binari event risk noth major come mind could stealth upsid surpris biosimilar
avastin/rituxan/herceptin delay us on-going patent litig
near-term outlook ep growth like flattish sure clariti emerg
battl oppos forc pipelin vs biosimilar
long-term outlook ep growth least model compress biosimilar eros across three
mega-brand give lowest ep compound-annual-growth-rate group
valuat price-to-earnings basi trade line group averag
net strike versu peer compani breadth current
pipelin testament best-in-class compani belief despit pipelin
investor attent would like overwhelm prospect roch three biggest drug
repres front end gener entri time clear fast
type product erod earli sign least ex-u promis howev
recent month investor will look past biosimilar uncertainti bull argu rog
valuat alreadi reflect concern futur valu pipelin under-estim
possibl least current model earn estim begin trail consensu fair
degre make difficult name construct also make slowest grower
group next sever year name worth watch see thing evolv urgenc
step one upsid scenario biosimilar us get delay assert
infring varieti compani three major brand
discontinu anti-amyloid antibodi crenezumab program earli alzheim diseas
futil interim anti-amyloid antibodi ganterumab continu higher dose
report result beat sale ep new sale ep guidanc
slightli ahead consensu detail see full postview
tecentriq avastin chemotherapi nsclc product alreadi approv us
page
file kadcyla adj earli breast cancer w/ residu diseas neoadjuv
treatment base katherin
fda accept prioriti review file two oncolog product polatuzumab vedotin
r/r dlbcl entrectinib ntrk solid tumor nsclc
announc acquisit bring gene therapi
space lead asset haemophilia
import upcom event next
approv combo chemo sclc tnbc
readout combo alimta chemo nsclc final os analysi atezo
mono nsclc combo chemo neoadjuv tnbc
mono combo platinum-bas chemo muc combo bevacizumab
combo cotel vs pembrolizumab braf melanoma
other
read-out combo w/ bortezomib r/r mm bellini other
polatuzumab approv r/r nhl pola rchp dlbcl polarix readout end
entrectenib approv ntrk solid tumor nsclc ignyta
risdiplam splice modifi file sma type earli posit data alreadi
present
htt-aso antisens huntington trial start late earli file possibl base follow-
initi pk studi cognit exploratori endpoint
etrolizumab anti-integrin crohn diseas read-out
idasanutlin inhibitor r/r aml combin cytarabin mirro read-out
page
biosimilar litig difficult know timelin news flow could
best-in-class engin late-stag pipelin proven within outsid oncolog
 ocrevu hemlibra best develop game-chang standard-of-car market re-
defin drug albeit first wave io late-stag pipelin brim
world-lead diagnost divis class ventana fmi flatiron health
synergi pharma busi drug compani type in-hous diagnost
capabl competit advantag whose benefit becom obviou time
assum precis medicin continu advanc
biosimilar fear well-known bake investor talk rog
biosimilar issu year stock alreadi discount uncertainti
us biosimilar delay assert patent herceptin rituxan
avastin multipl parti could conceiv delay biosimilar entri us would
upsid larg off-the-radar investor
biosimilar overhang stori killer still lot uncertainti around ultim trajectori
biosimilar eros play weve seen far eros faster harsher
expect least europ us could biosimilar adopt continu acceler faster
analyst expect possibl us end erod fast europ seem like given
widespread stakehold support ensur biosimilar adopt fda make biosimilar fulli
interchang substitut thing seem head direct could acceler
big grow revenu base around chf largest compani group
take lot move earn needl compani size
manag dividend deliv ep growth hoffman-oeri famili hold
control major vote share econom reward hold share come dividend
paid necessarili share price appreci see dont sell share maintain major
ownership leav open possibl interest align extern sharehold
page
outlook biggest market product collect chf total
rituxan variou cancer chf one world biggest cancer drug tail end
life-cycl biosimilar launch eu us next
avastin variou cancer chf anoth one world biggest cancer drug tail
end life-cycl biosimilar launch
herceptin breast cancer chf yet anoth one world biggest cancer drug
similarli tail end life-cycl biosimilar launch eu recent us occur
perjeta breast cancer chf use conjunct herceptin commonli grow
well help much blunt herceptin declin keep overal franchis flat
ocrevu multipl sclerosi best-in-class efficaci grow incred well despit
crowd space least rrm ppm true monopoli competitor ofatumumab sq
read rrm
pipelin asset gener later-stag candid visibl higher describ
risdiplam splice modifi pivot studi type firefish type sunfish
spinal muscular atrophi sma interim clinic data present look encourag hard
line competit like incumb nusinersen potenti gene therapi approach due
small trial size differ endpoint high level risdiplam look within least ballpark
activ nusinersen add option oral avail vs inject although valu oral
newborn popul remain debat compani estim chf opportun guid
acceler file
polatuzumab dlbcl earlier stage develop variou b-cell
malign fda btd ema prime dlbcl base encourag complet respons rate
phase file februari acceler approv like confirmatori pola rchp
tecentriq indic expans true pipelin product per se alreadi approv treat
bladder cancer nsclc seek expans earlier line lung cancer treatment well
tumor type despit histor cancer compani compani found play
catch-up field mani thought would domin analyst still forecast multi-billion peak sale
prove grow becom major immuno-oncolog contend
page
venclexta indic expans true pipelin product per se approv r/r cll
without del expans earlier line cll treatment tumor type aml mm
mcl partli live imbruvica shadow novel highli activ drug kol academ
center embrac drug fear pervad within commun set around drug safeti profil
low risk tumor lysi syndrom probabl deserv attent receiv today great
opportun broadli combin imbruvica one two punch econom share
faricimab bispecif mab formerli novel bispecif object improv
efficaci current vegf standard care current two phase trial dme yosemit rhine
go head-to-head regn eylea first read also investig
two area know well least us lucenti initi data doesnt seem show much
entrectinib ignyta acquisit pivot solid tumor trk
mutat rel modest commerci opportun given genom aberr rare
compet loxo larotrectinib smaller commerci opportun
ipatasertib akt inhibitor phase tnbc mbc
follow encourag phase result lotu
help inform rog biomarker-driven registr program robust interim os hazard ratio
first phase result expect partner array biopharma arri smaller
htt-aso antisens mutant huntington protein huntington diseas began phase
phase data show decreas csf mhtt protein exploratori analys show cognit
etrolizumab anti-integrin extens program inflammatori bowel disord eight on-going
trial includ two trial market-lead agent humira howev program
doesnt seem get talk much either investor compani phase read-out
balovaptan receptor inhibitor phase autism adult result arent expect
late fda breakthrough therapi design base encourag phase result
vanilla present imfar area high unmet need drug-bas therapeut option
current avail also investig children adolesc patient seem high risk
anti-myostatin phase develop duchenn muscular dystrophi dmd read-out
anticip earli phase data present demonstr increas lean bodi mass
muscl volum lead pivot program initi licens
idasanutlin inhibitor phase r/r aml combin cytarabin mirro read-out
anticip late earli os primari endpoint wild type subpopul earli efficaci
signal encourag cr rate dose investig combo potenti venclexta
current phase smaller commerci opportun
page
alzheim one unusu anti-amyloid beta mab develop one
roch gantenerumab one genentech crenezumab crenezumab discontinu
futil januari gantenerumab similar biib aducanumab target a-beta plaqu
initi pivot program fail push forward higher dose read-out earli
page
valuat current price-to-earnings multipl among cheapest full comp sheet see exhibit trade
price-to-earnings multipl ep ep ep
use target price-to-earnings multipl appli ep arriv year end price target
use price target multipl across cover compani rang
rog incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
sanofi san pp pt lower expect name upsid case elus
compani report factset wolf research price
page
wolf bullet-point view san
investor sentiment interest build slowli growth return hope new cfo
would cut cost expect
pipelin prowess abil clearli weaker end histor current
pipelin thin san chang head step right direct whether san
truli fix remain tbd
binari event risk much major event think on-going praluent litig
could theoret lead product withdraw saga continu
near-term outlook ep growth rebound last three year flattish/down bit
light catalyst
long-term outlook steadi grower modest level per forecast
valuat among cheapest stock group price-to-earnings multipl basi usual case
net given san lower valuat often case like
lot downsid risk stori extend period growth modest clear
san prospect histor among weakest sector get better anytim soon new
head hire sometim come month unveil vision futur
turn around fail often succe even succeed take long time
deeper invest mean spend could rise tried-and-tru quicker way gain
bigger pipelin earlier san spent purportedli earmark
acquisit two differ deal one introduc new uncertainti wont like
enough chang earn trajectori meaning enough view prior hope manag
final cut cost greater degre realiz sit sidelin
announc posit phase data icaria-mm trial test isatuximab combin
pomalidomid dexamethason rrmm regulatori submiss plan later
announc fda approv cablivi caplacizumab attp prioriti review
report result in-lin revenu ep guidanc in-lin w/
estim slightli lower spend
announc new reduc us list price praluent new list price expect
lower earli march
page
juri verdict rule favor patent claim relat antibodi san
appeal
import upcom event next
file chronic rhinosinus nasal polyp
pdufa adolesc atop dermat
regulatori decis eu ja asthma
readout atop dermat year old
isatuximab result recent toplin posit us eu submiss combo w/
pomalidomid dexamethason expect
fitusiran sirna target antithrombin hemophilia atla readout expect
poc readout moderate-to-sever asthma mono combo w/ dupix
expect
john reed new head vision futur brief updat provid earn
like come sanofi investor meet pari june
patent litig vs san/regn mix set rule thu far san/regn timelin
resolut like extend
new cfo final cut cost new cfo jean-baptist chasseloup de chatillon hail outsid
pharmaceut industri formerli french automobile/motorcycl compani track
record suggest could cut cost expect
dupilumab sit front renew growth roll asthma self-administ
best-in-class data also roll broader age rang atop dermat patient
page
one lowest valuat lowest expect drug stock mean limit downsid sum
part basi upsid steadili grow busi like vaccin consum genzym
carri much higher multipl wolf comment view sotp analys appropri
compani commit split divis like gsk eventu consum
compani larg move beyond patent cliff start consist
revenu ep growth next mani year lantu declin lessen
sanofi track record weak keep price-to-earnings multipl compress reed clean
hous could disrupt spend like step burden already-slow
commerci perform lead drug lantu remain challeng get complic
less time addit biosimilar beyond two franchis collect sold
eur account total compani revenu mean san still lot exposur
area remain declin insulin remain target us polit standpoint hard see
evolv materi risk san
dupilumab competit atop dermat far behind varieti competitor albeit
differ mechan action mostli jak inhibit would mean oral deliveri first phase data
separ compound
bioverativ acquisit put san right middl controversi name lead product
eloct fare launch hemlibra possibl new entrant gene therapi
outlook biggest market product collect eur total
lantu diabet end life-cycle eros continu due brand
competit biosimilar entrant
aubagio multipl sclerosi weaker cleaner oral ms drug vs gilenya still
growth stage life-cycl commerci success surpris rel initi expect us loe
dupix atop derm asthma third year launch strong
autoimmun diseas limit potenti indic expect becom
competit
page
plavix cardiovascular anoth post-lo product sustain sale emerg market
still big enough make top list san growth brand howev
lovenox anti-thrombot dvt/pfe prevent declin steadili due gener
competit multipl market difficult make howev slow rate eros
pipelin asset gener later-stag candid visibl higher includ
dupilumab indic expans true pipelin product per se partner
regeneron alreadi approv atop dermat moderate-to-sever asthma potenti indic
expans nasal polyp sbla expect eosinophil esophag copd other
cemiplimab inh indic expans true pipelin product per se partner
regeneron recent first approv us cutan squamou cell carcinoma cscc small indic
trial run multipl tumor includ nsclc cervic combo trial w/
chemotherapi also run regulatori success highli like commerci success like elus
late-entr statu
isatuximab inh phase trial relapsed/refractori multipl myeloma icaria posit
ikema expect phase trial newli diagnos multipl myeloma ndmm start
decemb recent grant orphan drug statu fda ema moder commerci
expect primarili darzalex handili beat san market first us approv
caplacizumab anti-vwf nanobodi attp acquir part ablynx recent approv eu
us expect small revenu opportun
start comet phase pomp diseas primari complet octob
fitusiran sirna target antithrombin hemophilia rnai therapeut san collabor
alnylam full right given san clinic hold briefli phase
sotagliflozin dual inh licens lexicon pharmaceut three recent
posit phase readout diabet phase trial diabet start recent
split decis fda emdac benefit risk profil fda pdufa march ema decis
remain seen differenti might occur inhibit exist product
focus latter tough see truli differenti differenti may
good way higher gi tox inhibit
page
growth profil steadi modest level
valuat current price-to-earnings among cheapest full comp sheet see exhibit san trade price-to-earnings
multipl ep ep ep use
target price-to-earnings multipl appli ep arriv year end price target use
price target multipl across cover compani rang
san incom statement revenu forecast balanc sheet/cash flow statement see appendix
financi statement end report
page
page
incom statement oper expens foreign exchang incom expens outstand margin total profit profit profit incom growth oper revenu earli phase total
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ chang short-term issuanc lt lt debt leas treasuri flow financ activ fx cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock held paid-in comprhens sharehold liabil sharehold
page
incom statement except revenu initi good profit ens oper incom incom financ profit incom incom azn share mm margin product sale exclud good margin total total margin total margin pre-r total margin total margin total rate good profit ens incom incom incom outstand
page
page
summari statement incom amort work non-cash cash provid short-term invest fix purchas purchas intang purchas non-curr asset made subsidiari non-control cash provid use invest purchas short term borrow cash provid use financ increas decreas begin rate end sheet cash equival market account incom tax current current properti plant goodwil tax current term tax benefit non-curr premium sharehold
page
incom statement except oper interest incom incom expens non-gaap share mm analysi good equiti outstand revenu w/pfe total total reyataz baraclud hcv total orencia orencia total matur product total earli stage factor- total
page
summari statement incom attribut non-controlling incom tax expens comp work cash provid purchas market ppe capit sale cash provid use invest purchas rate swap cash provid use financ exchang rate icreas decreas cash sheet cash equival market account current current properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold sharehold
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total prasugrel share total total primari taltz ixekizumab olumi baricitinib jak emgal galcanezumab anti-cgrp migrain total specialti total earli stage factor- total anim total
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
page
incom statement revenu exclud sale revis profit revis revis revis ens revis profit revis financ inc/ profit revis revis incom revis interest viiv nvs/pfe chc sharehold revis pavg share million total margin revis revis revis oper margin revis rate revis margin revis profit revis revis revis profit revis incom revis incom revis revis outstand
page
revenu gbp laba/lama close stage sale includ
page
summari statement ventur dispos interest invest servic non- work net cash provid purchas properti plant purchas intang invest associ joint cash provid use invest treasuri shares/shar chang short term cash provid use financ exchang rate cash increas decreas end balanc sheet cash properti plant goodwil current term non-curr capit call premium earn profit loss sharehold minor employ total
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
product revenu daili total isentress remicad simponi zepati biosimilar viral vaccin proquad varivax pneumovax comvax pedvaxhib gardasil januvia dulera allergi women bridion keytruda onc pain product earli phase revenu incl lynparza total
page
flow statement incom incom distribut equiti incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
page
incom statement product incom net incom basic novn use outstand total product profit profit incom product incom outstand
page
page
flow statement incom cont amort revers non-cash flow work capit provis net current asset oper cash flow flow oper activ tangibl fix intang flow invest activ treasuri non-curr financi flow financ activ increas decreas cash sheet plant non-curr long term account current cash current treasuri share debt lt long-term long term account debt short-term liabil sharehold
page
incom statement incom outstand total profit profit incom
page
page
flow statement earn in-process sale impair restructur defer compens asset flow oper activ sale sale busi net invest flow invest activ chang short term repay long-term common dividend flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr stock cent par valu paid-in comprehens treasuri stock sharehold liabil sharehold
page
incom statement chf salessfr oper incomesfr revenuessfr sfr profitsfr distributionsfr profitsfr financi incom sfr financi expens -sfr financi income-sfr profitsfr taxessfr incomesfr incom rochesfr basic core sfr dilut core sfr outstand outstand product profit profit profit
page
product revenu chf ww incl sq form sfr wwsfr info wwsfr wwsfr ww incl sq form sfr wwsfr wwsfr wwsfr alectinib alki wwsfr cobimetinib mek inhibitor wwsfr atezolizumab wwsfr wwsfr recormon/epoginsfr b-cell malign wwsfr aml wwsfr akt inh solid tumor wwsfr cancer wwsfr oncologysfr total pharma bi-specif ixa/x wwsfr ocrelizumab ww sfr ww alz dz sfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr wwsfr ww parkinson sfr earli stage pipelin sfr pharma salessfr caresfr diagnost incl ind bu sfr diagnosticssfr diagnost ventana sfr diagnost salessfr total revenuessfr
page
flow statement chf incomesfr incomesfr costssfr taxessfr profitsfr ppesfr intangiblessfr gener operationssfr decreas work capitalsfr tax paidsfr flow oper activitivi cfo sfr ppe-sfr intang assets-sfr flow invest activ cfi -sfr decreas long-term debt-sfr equiti instrumentssfr decreas short-term borrowings-sfr paid-sfr paid-sfr flow financ activ cff -sfr effect currenc translat cashsfr increas decreas cash equiv sfr sheet chf assetssfr long-term assetssfr receiv tradesfr incom tax assetssfr securitiessfr equivalentssfr current assetssfr assetssfr debtsfr incom tax liabilitiessfr non-curr liabilitiessfr debtsfr payabl trade othersfr current liabilitiessfr liabilitiessfr capitalsfr earningssfr reserve-sfr equiti attribut rogsfr interestsfr equitysfr
page
incom statement except revenu current op inc /exp royalti incom profit/ loss assoc incom attrib minor interest oper financi incom associ non-control tax net euro excl select item share mil margin product incom tax share profit incom excl select outstand
page
page
summari statement net incom amort chang defer taxes- cash flow chang work capital- work capit cash provid oper ppe capit software- acquisitions- chg loan non-curr financi assets- cash provid use invest activities- paid- chang short-term borrow chang long-term debt chang capit stocks- financial- cash provid use financ activities- exchang rate equivalents- increas decreas end period sheet cash equival current financi asset account receiv inventori current asset current asset properti plant equip goodwil intang asset asset payabl current liabil term debt term debt tax liabil non-curr liabil liabil equiti interest minor sharehold sharehold equiti liabil sharehold equiti
